Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6271 to 6285 of 8223 results

  1. Monitoring inhaler technique:- What is the current frequency and the current method being used to check the inhaler technique of people with asthma? What is the optimal frequency and the best method of checking inhaler technique to improve clinical outcomes for people with asthma?

    Recommendation ID NG80/4 Question Monitoring inhaler technique:- What is the current frequency and the current method being used to check

    Research recommendation
    Published
    18 October 2018

  2. Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine assessment and monitoring of changes in pulmonary status in people with cystic fibrosis?

    Recommendation ID NG78/3 Question Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine

    Research recommendation
    Published
    6 November 2018

  3. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Recommendation ID CG173/1 Question What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy

    Research recommendation
    Published
    26 October 2020

  4. Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Recommendation ID CG173/1 Question Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness

    Research recommendation
    Published
    9 June 2015

  5. More research is needed on the following artificial intelligence (AI)‑derived software to analyse chest X‑rays alongside clinician review for suspected lung cancer in adults referred from primary care:

    Recommendation ID HTE12/1 Question More research is needed on the following artificial intelligence (AI)‑derived software to analyse chest

    Research recommendation
    Published
    11 January 2024

  6. More research is needed on the following key outcomes:

    Recommendation ID HTE12/1 Question More research is needed on the following key outcomes: Any explanatory notes(if applicable)

    Research recommendation
    Published
    11 January 2024

  7. More research is needed on using the following digital weight-management technologies:

    Recommendation ID HTE14 Question More research is needed on using the following digital weight-management technologies: Any explanatory

    Research recommendation
    Published
    11 January 2024

  8. More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee replacement would decrease the uncertainty of the clinical and cost effectiveness of these treatments. Trials directly comparing apixaban with rivaroxaban, dabigatran etexilate and fondaparinux would strengthen the evidence base for these comparisons.

    Recommendation ID TA245/1 Question More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee

    Research recommendation
    Published
    9 June 2015

  9. NICE recommends research generating and analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim.

    Recommendation ID TA293/2 Question NICE recommends research generating and analysing observational data including, but not limited to,

    Research recommendation
    Published
    9 June 2015

  10. [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.

    Recommendation ID TA161/2 Question [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the

    Research recommendation
    Published
    9 June 2015

  11. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    Recommendation ID TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts

    Research recommendation
    Published
    9 June 2015

  12. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    Recommendation ID TA274/1 Question NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab

    Research recommendation
    Published
    9 June 2015

  13. NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice.

    Recommendation ID TA293/1 Question NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin

    Research recommendation
    Published
    9 June 2015

  14. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Recommendation ID TA254/1 Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related

    Research recommendation
    Published
    9 June 2015

  15. NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the following arrangements are in place: - coordination of eculizumab use through an expert centre - monitoring systems to record the number of people with a diagnosis of atypical - haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment - a national protocol for starting and stopping eculizumab for clinical reasons - a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur.

    Recommendation ID HST1/1 Question NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the

    Research recommendation
    Published
    9 June 2015